July 2025 News

Files for July 2025 amendments to the Medicare Benefits Schedule

Page last updated: 03 June 2025

The 1 July 2025 MBS files are available on the July 2025 Downloads Page.

Summary of MBS Changes for 1 July 2025

From 1 July 2025, there will be changes to the MBS. These changes include annual fee indexation and a range of administrative and policy changes to implement the Government’s response to recommendations from the MBS Review Taskforce (the Taskforce) and the Medical Services Advisory Committee (MSAC). The changes will affect the:

Indexation

From 1 July 2025, annual fee indexation will be applied to:
  • most of the general medical services items;
  • most diagnostic imaging services (excluding: positron emission tomography (PET) items and nuclear medicine modifier items); and
  • pathology items in Group P1, Group P4, Group P5, Group P6, Group P8 and Group P12.
The MBS indexation factor for 1 July 2025 is 2.4 per cent.

Chronic Condition Management Changes

From 1 July 2025, changes will be made relating to chronic condition management arrangements under the MBS. These changes include:
  • Replacing the existing two plan (GP management plan and team care arrangements) framework with a single planning item for chronic conditions (GP chronic condition management plan);
  • Aligning the fees for developing and reviewing chronic condition management plans;
  • Implementing transitional arrangements from 1 July 2025 to 30 June 2027 allowing patients to continue accessing follow on services under GP management plans and team care arrangements put in place prior to 1 July 2025;
  • Introducing new telehealth attendance items for preparation and review of GP chronic condition management plans by general practitioners (GPs) and prescribed medical practitioners (PMPs);
  • Introducing a requirement for patients to have received a planning service or review service in the last 18 months to continue accessing allied health services under a GP chronic condition management plan; and
  • Revising the referral requirements for specified allied health services.
These changes were endorsed by the Taskforce on the recommendation of the General Practice and Primary Care Clinical Committee (GPPCCC).

Other changes to general medical services

From 1 July 2025, changes will be made relating to general medical services. These changes include:
  • Introducing new and amending existing MBS items for ophthalmology services as recommended by the Taskforce or MSAC;
  • Introducing two new items (125 and 126) to provide gynaecology long consultation items for patients with complex conditions and consequential changes to items 104 and 105 as a result of the new items;
  • Consequential changes to items 132 and 133 as a result of new and amended changes to specialist and consultant physicians telehealth items;
  • Adding a co-claiming restriction to item 92614 for telehealth attendance by a specialist in the practice of neurosurgery;
  • Amending ten radiation oncology items (15930, 15932, 15934, 15936, 15938, 15940, 15942, 15944, 15946, 15948) for megavoltage treatment to clarify how often the items can be claimed, to update referenced item numbers, and to make further minor corrections to align with their original policy intent;
  • Introducing new item (38326) from MSAC recommendation for optical coherence tomography to guide coronary stent insertion in specific patient populations;
  • Administrative amendment to change the definition of 'Telehealth and Telephone Determination';
  • Introducing new item (15990) for proton-photon comparative planning services with retrospective application from 1 July 2024;
  • Introducing two new therapeutic nuclear medicine (16050 and 16055) for Lutetium prostate specific membrane antigen (PSMA) treatment;
  • Introducing new and amended MBS items for telehealth provided by specialist and consultant physicians;
  • Enabling eligible dietitians and exercise physiologists to claim MBS items (82030, 82035, 93033, 93036, 93041 and 93044) for patients with complex neurodevelopmental disorders and eligible disabilities;
  • Introducing two new radiography items (75010 and 75011) for cleft and craniofacial services;
  • Introducing temporary MBS items (695 and 19000) for health assessments targeting women experiencing menopause or perimenopause; and
  • MBS items for COVID-19 vaccine suitability assessments, and associated items, will cease from 1 July 2025 and general practitioners will be able to use general attendance items when assessing a patient’s suitability for a COVID-19 vaccination.

Changes to diagnostic imaging services

From 1 July 2025, changes will be made relating to diagnostic imaging services. These changes include:
  • Amending two whole body fluorodeoxyglucose PET study items (61612 and 61614) to remove the definition of rare or uncommon cancer;
  • Changing eligibility requirements for diagnostic imaging equipment;
  • Consequential changes to remove a reference to the Royal Australian and New Zealand College of Radiologists (RANZCR) Mammography Quality and Accreditation Program and remove cardiac MRI item 63390 from a maximum claiming limit on the item;
  • Administrative change to items 60506 and 60509, to clarify the time period referenced in each item relates to fluoroscopy and not the surgical procedure;
  • Introducing two new items (57410 and 57413) for low-dose CT scan of the chest as part of the National Lung Cancer Screening Program;
  • Introducing new item (61528) for whole body PSMA positron emission tomography study to determine eligibility for the treatment items; and
  • Update to the descriptor for MBS item (57541) to clarify that a mobile x-ray provider can also claim a ‘call out’ fee if an x-ray associated with item 57541 is requested by a participating nurse practitioner.

Changes to pathology services

From 1 July 2025, changes will be made relating to pathology services. These changes include:
  • Amending a urine examination pathology test (item 69333) to restrict testing to symptomatic and some asymptomatic patients to reduce clinically unnecessary testing;
  • Amending two vitamin B12 pathology tests (66838 and 66839) and list a new vitamin B12 pathology item (66842) for more frequent testing to clarify the appropriate testing pathway of vitamin B 12; and
  • Introducing new item (73319) for IDH1 variant testing in tumour tissue.

Relevant legislation

Please note links will be added as they become available on the Federal Register of Legislation

Search the MBS

News

Fact Sheets

Downloads